Articles tagged with Multiple Myeloma
The Mayo Clinic study found that the risk of progression from MGUS to multiple myeloma or related cancers is approximately one percent per year, with larger M-protein levels increasing the risk. Patients with very small protein levels had a 14% progression rate at 20 years, while those with high levels had a 60% progression rate.
A two-step approach combining high-dose chemotherapy and autologous stem-cell rescue with mini-transplantation from a sibling significantly reduces transplant-related complications and increases survival rates for patients with advanced-stage multiple myeloma. The procedure results in mild to moderate treatment-related toxicities and a...
The Mayo Clinic study found that thalidomide can stop or slow the progression of multiple myeloma in patients newly diagnosed with this cancer. Thalidomide was previously used to treat advanced myeloma, but this is the first published report documenting its effectiveness as a first-line treatment for early-stage multiple myeloma.
Phase II studies indicate that Mylovenge causes regression or stabilization in over 30% of patients with multiple myeloma and amyloidosis, with some benefits lasting up to 18 months. The vaccine stimulates the immune system to recognize and destroy cancer cells.